Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
2,093
NCT04505826
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 13, 2020
Completion: Jul 30, 2024
NCT05266105
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Phase: Phase 1
Start: Dec 10, 2021
Completion: Jul 31, 2025
NCT05508906
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Start: Aug 31, 2022
Completion: Jan 31, 2028
NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase: Phase 3
Start: Nov 16, 2023
Completion: Sep 30, 2027
NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Start: Dec 16, 2024
Completion: Aug 30, 2027
NCT07085767
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Start: Oct 31, 2025
Completion: Jan 31, 2032